12/3
04:05 pm
anro
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Low
Report
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
12/1
05:42 pm
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
Low
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
11/21
05:30 am
anro
Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/17
08:06 am
anro
Alto Neuroscience (NYSE:ANRO) is now covered by analysts at BTIG Research. They set a "buy" rating and a $27.00 price target on the stock.
High
Report
Alto Neuroscience (NYSE:ANRO) is now covered by analysts at BTIG Research. They set a "buy" rating and a $27.00 price target on the stock.
11/15
01:42 am
anro
Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at
Wall Street Ze
High
Report
Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at
Wall Street Ze
11/13
08:11 am
anro
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Robert W. Baird from $16.00 to $22.00. They now have an "outperform" rating on the stock.
High
Report
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Robert W. Baird from $16.00 to $22.00. They now have an "outperform" rating on the stock.
11/12
02:53 pm
anro
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $25.00. They now have a "buy" rating on the stock.
11/12
09:57 am
anro
Alto Neuroscience GAAP EPS of -$0.52 [Seeking Alpha]
Low
Report
Alto Neuroscience GAAP EPS of -$0.52 [Seeking Alpha]
11/12
07:57 am
anro
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Low
Report
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/11
09:21 am
anro
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days [Yahoo! Finance]
Medium
Report
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days [Yahoo! Finance]
10/28
07:34 am
anro
Alto Neuroscience to Participate in Upcoming Investor Conferences
Medium
Report
Alto Neuroscience to Participate in Upcoming Investor Conferences
10/24
08:06 am
anro
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at HC Wainwright from $10.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at HC Wainwright from $10.00 to $50.00. They now have a "buy" rating on the stock.
10/20
02:08 pm
anro
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Robert W. Baird from $10.00 to $16.00. They now have an "outperform" rating on the stock.
Low
Report
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Robert W. Baird from $10.00 to $16.00. They now have an "outperform" rating on the stock.
10/20
07:03 am
anro
Alto Neuroscience Announces $50 Million Private Placement Financing
High
Report
Alto Neuroscience Announces $50 Million Private Placement Financing
10/20
07:01 am
anro
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
High
Report
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
10/8
09:56 am
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
Medium
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
10/7
06:05 pm
anro
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/6
08:58 am
anro
Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate [Yahoo! Finance]
Medium
Report
Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate [Yahoo! Finance]
10/3
10:51 am
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
Medium
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
10/3
07:44 am
anro
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia [Yahoo! Finance]
High
Report
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia [Yahoo! Finance]
10/3
07:34 am
anro
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
High
Report
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
9/29
08:05 am
anro
Alto Neuroscience (NYSE:ANRO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $15.00 price target on the stock.
Neutral
Report
Alto Neuroscience (NYSE:ANRO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $15.00 price target on the stock.
9/22
10:02 am
anro
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
Medium
Report
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
9/19
06:30 pm
anro
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
Medium
Report
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
9/19
04:49 pm
anro
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
Medium
Report
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO